There are 2789 resources available
1095TiP - Daromun, a dermato-oncology drug in development for stage III and IV melanoma and non-melanoma skin cancers: A clinical overview
Presenter: Katharina Kähler
Session: ePoster Display
1102P - The phase III NETTER-1 study of 177Lu-DOTATATE in patients with midgut neuroendocrine tumours: Further survival analyses
Presenter: Philippe Ruszniewski
Session: ePoster Display
1103P - 177Lu-DOTATATE efficacy and safety in functioning neuroendocrine tumors: A joint analysis of phase II prospective clinical trials
Presenter: Alberto Bongiovanni
Session: ePoster Display
1104P - Functional imaging and clinical outcomes in grade 3 neuroendocrine tumors (NETs G3): A single-center retrospective analysis
Presenter: Alice Laffi
Session: ePoster Display
1105P - Predictive factors of adverse events onset in GEPNET patients treated with PRRT
Presenter: Federica Scalorbi
Session: ePoster Display
1023P - A novel microbiome-derived peptide, SG-3-00802 reverses resistance to anti-programmed death protein-1 (PD-1) therapy
Presenter: Helena Kiefel
Session: ePoster Display
1025TiP - SOLTI-1904: Efficacy of spartalizumab across multiple cancer-types in patients with PD1-high mRNA expressing tumors defined by a single and pre-specified cutoff (ACROPOLI)
Presenter: Aleix Prat
Session: ePoster Display
1026TiP - A phase Ib/II, open-label, multicenter, dose-escalation and dose-expansion study of NKTR-255 plus cetuximab as a salvage regimen in patients with solid tumors
Presenter: Mehmet Altan
Session: ePoster Display
1027TiP - A phase Ib study of CM24 in combination with nivolumab in adults with advanced solid tumors, followed by a phase IIa study of CM24 in combination with nivolumab in NSCLC, and in combination with nivolumab and nab-paclitaxel in pancreatic cancer
Presenter: Erkut Borazanci
Session: ePoster Display